<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01698450</url>
  </required_header>
  <id_info>
    <org_study_id>EK: 2012-0027</org_study_id>
    <nct_id>NCT01698450</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance (MR) Guided Functional Ultrasound-Neurosurgery for Movement Disorders</brief_title>
  <official_title>MR-Guided Functional Ultrasound-Neurosurgery for Movement Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Children's Hospital, Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Children's Hospital, Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to asses the efficacy and the clinical safety of the transcranial
      magnetic resonance guided high intensity focused ultrasound system ExAblate 4000, InSightec
      Ltd. for functional neurosurgery in the treatment of movement disorders. The treatments to be
      conducted in this study are non-invasive, i.e. without opening the skull, and will create
      microthalamotomies in specific target areas such as thalamus, subthalamus and pallidum. The
      data obtained in this study will be used to evaluate the basic safety aspects of this new
      treatment technology and will serve as a basis for the clinical introduction of MR-guided
      ultrasound neurosurgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lesion Size</measure>
    <time_frame>3 months</time_frame>
    <description>Size of lesion in the target area for each sonication as a function of applied energy/temperature.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Safety</measure>
    <time_frame>3 months</time_frame>
    <description>Number of Patients with Adverse Events as a Measure of Safety and Tolerability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy and QOL</measure>
    <time_frame>3 months</time_frame>
    <description>Efficacy and QOL will be quantified on respective rating scales (specified in protocol).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Essential Tremor</condition>
  <condition>Dystonia</condition>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Focused Ultrasound for Movement Disorders</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non-invasive intervention with focused ultrasound (ExAblate 4000)</intervention_name>
    <description>Non-invasive brain intervention using MR-guided focused ultrasound</description>
    <arm_group_label>Focused Ultrasound for Movement Disorders</arm_group_label>
    <other_name>ExAblate 4000</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, between 18 and 80 years, inclusive.

          -  Patients who are able and willing to give consent and able to attend all study visits.

          -  A diagnosis of a MD, such as Essential Tremor (ET), Idiopathic Parkinson's diseases or
             primary Dystonia as confirmed from clinical history and examination by a movement
             disorder neurologist.

          -  A MD refractory to adequate medical treatment, or in whom the indication for Deep
             Brain Stimulation (DBS) would be given, but DBS cannot be performed because of medical
             comorbidities or medical reasons, or because the patient clearly confirms by written
             statement that he does not want to undergo DBS for personal reasons (PD: increasing
             motor fluctuations albeit optimal medical treatment &amp; unbearable side effects of
             medication; ET: failure of adequate tremor control with Propranolol and Primidone
             alone and in combination; Dystonia: dystonia or pain not controlled by oral
             medication). An adequate medication trial is defined as a therapeutic dose of each
             medication or the development of side effects as the medication dose is titrated.

          -  Either the medial thalamic nuclei or the subthalamic or pallidal areas can be target
             by the ExAblate device. The target region must be apparent on MRI such that targeting
             can be performed with either direct visualization or by measurement from landmarks,
             using the &quot;Stereotactic Atlas of the Human Thalamus and Basal Ganglia&quot; by Anne Morel,
             39 analogous to our first clinical FUS study on patients with chronic pain 33.

          -  Able to communicate sensations during the ExAblate MRgFUS treatment

          -  Stable doses of all medications for 30 days prior to study entry and for the duration
             of the study.

          -  Significant disability due to MD despite medical treatment (speaking, feeding other
             than liquids, bringing liquids to mouth, hygiene, dressing, writing, working, and
             social activities)

          -  Inclusion and exclusion criteria have been agreed upon by two members of the medical
             team.

        Exclusion Criteria:

          -  Patients with unstable cardiac status including:

               -  Unstable angina pectoris on medication

               -  Patients with documented myocardial infarction within six months of protocol
                  entry

               -  Congestive heart failure requiring medication (other than diuretic)

               -  Patients on anti-arrhythmic drugs

          -  Patients exhibiting any behavior(s) consistent with ethanol or substance abuse as
             defined by the criteria outlined in the DSM-IV as manifested by one (or more) of the
             following occurring within a 12 month period:

               -  Recurrent substance use resulting in a failure to fulfill major role obligations
                  at work, school, or home (such as repeated absences or poor work performance
                  related to substance use; substance-related absences, suspensions, or expulsions
                  from school; or neglect of children or household).

               -  Recurrent substance use in situations in which it is physically hazardous (such
                  as driving an automobile or operating a machine when impaired by substance use)

               -  Recurrent substance-related legal problems (such as arrests for substance related
                  disorderly conduct)

               -  Continued substance use despite having persistent or recurrent social or
                  interpersonal problems caused or exacerbated by the effects of the substance (for
                  example, arguments with spouse about consequences of intoxication and physical
                  fights).

          -  Severe hypertension (diastolic BP &gt; 100 on medication)

          -  Patients with standard contraindications for MR imaging such as non-MRI compatible
             implanted metallic devices including cardiac pacemakers, size limitations, etc.

          -  Known intolerance or allergies to the MRI contrast agent (e.g. Gadolinium) including
             advanced kidney disease

          -  Severely impaired renal function (estimated glomerular filtration rate &lt; 45ml/min/
             1.73 m2) or receiving dialysis

          -  History of abnormal bleeding and/or coagulopathy

          -  Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within
             one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage
             (e.g. Avastin) within one month of focused ultrasound procedure

          -  Active or suspected acute or chronic uncontrolled infection

          -  History of intracranial hemorrhage

          -  Cerebrovascular disease (multiple CVA or CVA within 6 months)

          -  Individuals who are not able or willing to tolerate the required prolonged stationary
             supine position during treatment (can be up to 4 hrs of total table time.)

          -  Symptoms and signs of increased intracranial pressure (e.g. headache, nausea,
             vomiting, lethargy, and papilledema)

          -  Participation in another clinical trial in the last 30 days

          -  Patients unable to communicate with the investigator and staff.

          -  Presence of any other neurodegenerative disease like Parkinson-plus syndromes
             suspected on neurological examination. These include: multisystem atrophy, progressive
             supranuclear palsy, dementia with Lewy bodies, and Alzheimer's disease.

          -  Presence of significant cognitive impairment as determined with a score â‰¤ 24 on the
             Mini Mental Status Examination (MMSE)

          -  Compromised Immune System, including HIV positive serum status

          -  Known life-threatening systemic disease

          -  Patients with a history of seizures within the past year

          -  Patients with current or a prior history of any psychiatric illness will be excluded.
             Any presence or history of psychosis will be excluded. Patients with a significant
             mood disorders including depression will be excluded. For the purpose of this study,
             we consider a significant mood disorder to include any patient who has:

               -  been under the care of a psychiatrist for over 3 months

               -  taken antidepressant medications for greater than 6 months

               -  has participated in cognitive-behavioral therapy

               -  been hospitalized for the treatment of a psychiatric illness

               -  received transcranial magnetic stimulation

               -  received electroconvulsive therapy

          -  Patients with risk factors for intraoperative or postoperative bleeding (platelet
             count less than 100,000 per cubic millimeter, PT &gt; 14, PTT &gt; 36 or INR &gt; 1.3) or a
             documented coagulopathy

          -  Patients with brain tumors

          -  Any illness that in the investigator's opinion preclude participation in this study.

          -  Pregnancy or lactation.

          -  Legal incapacity or limited legal capacity.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernst - Martin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Children's Hospital, Zurich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald - Bauer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurosurgey, Kantonsspital St. Gallen, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MR-Center, University Children's Hospital</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2012</study_first_submitted>
  <study_first_submitted_qc>September 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2012</study_first_posted>
  <last_update_submitted>October 8, 2014</last_update_submitted>
  <last_update_submitted_qc>October 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FUS</keyword>
  <keyword>focused ultrasound</keyword>
  <keyword>functional brain disorder</keyword>
  <keyword>neuropathic pain</keyword>
  <keyword>movement disorders</keyword>
  <keyword>malignant brain tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Movement Disorders</mesh_term>
    <mesh_term>Essential Tremor</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

